Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Verrica Pharmaceuticals (NASDAQ: VRCA) announced that President and CEO Jayson Rieger will present at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 11:05 a.m. ET, with a live and replay webcast available via Verrica’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – VRCA
In the May 28 session, VRCA declined 0.41%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Investor conference | Neutral | +3.1% | Participation in H.C. Wainwright BioConnect investor conference at NASDAQ. |
| May 12 | Earnings results | Positive | +3.1% | Q1 2026 results with YCANTH revenue growth and higher dispensed units. |
| May 05 | Clinical data update | Positive | +17.7% | Phase 2 VP-315 data showing tumor size reduction and clearance in BCC. |
| May 05 | Earnings date set | Neutral | +12.6% | Announcement of date and details for Q1 2026 results and webcast. |
| Apr 09 | Abstract acceptance | Positive | -12.3% | Acceptance of late-breaking abstract on VP-315 abscopal effect for SID 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been followed by positive price reactions, particularly around clinical data and earnings, with one notable negative reaction to an abstract acceptance despite its seemingly positive content.
Over the last few months, Verrica has highlighted multiple investor and scientific conference appearances, earnings updates, and clinical progress. Events on May 12–13, 2026 combined Q1 results and an investor conference, both followed by modest gains of 3.08%. Phase 2 VP-315 data on May 5, 2026 coincided with a stronger 17.74% move, while acceptance of related data on April 9, 2026 saw a -12.35% reaction, underscoring occasionally divergent trading around similar scientific updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.
Jefferies Global Healthcare Conference, June 2-4, 2026
Event details:
Date: Thursday, June 4, 2026
Time: 11:05am ET
Location: New York
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
